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There are several differences in the study design that could
theoretically explain contradictory results.
Robbin et al.1 included subjects later after surgery – the
mean graft age was 9 months at inclusion, while we performed
inclusion and first ultrasound examination within 4 weeks
after access creation. We could hypothesize that high-risk
grafts, which thrombose within first year after access creation,
were therefore not included into Robbin’s study. Such patients
probably profit from ultrasound surveillance most.
Another difference is that although Robbin et al.1
performed a single-center study, our patients were hemodia-
lyzed in 25 centers. Although all dialysis centers in our study
made every effort to follow K/Dialysis Outcome Quality
Initiative guidelines, their experience could vary. Access flow
was monitored in less than 50% of patients in our study.
These factors could increase the profit of ultrasound
surveillance in our study. We think that multi-center study
reflects better routine care, which is probably less perfect than
in highly specialized hemodialysis units of university
hospitals. On the contrary, in the light of Dossabhoy’s study,
higher use of access flow monitoring would probably not
change dramatically our results.
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We thank Dr Malik1 for his interest. Our average graft age
at enrollment was 8.877.3 months,2 whereas Malik’s
patients were enrolled by 1 month.3 Malik’s study showed
a significant difference between control and ultrasound
group by 6 months of graft age. We potentially did not
enroll some problematic grafts that failed by 6–9 months.
However, 27% of our grafts had a prior thrombectomy, and
33% had a prior percutaneous transluminal angioplasty.
Furthermore, our subgroup analysis of 57 ‘virgin’ grafts
(45%) showed no significant difference in time to graft
failure or thrombosis-free survival between the ultrasound
and control group. Thus, the difference between the study
results is unlikely to be owing to graft age at enrollment.
Additionally, even after 9 months, Malik’s data show a
continued steep decline in the access patency of control
group grafts, not demonstrated in our data.
Our data represent five University of Alabama centers
with fairly uniform graft assessments. Practice patterns may
differ more widely between the 25 centers in Malik’s study.
Access flow was monitored in about 50% of the control
patients in Malik’s study. We performed comparable
routine graft clinical monitoring, but did not perform
access flow, dynamic pressure, or recirculation measure-
ments. The study differences may be due, in part, to our
more frequent routine clinical monitoring. Angioplasty
versus thrombectomy frequencies for Malik’s groups
would be useful in this assessment.
Ultrasound can detect graft stenoses that are not
clinically significant.4 However, no benefit of pre-emptive
angioplasty in clinically asymptomatic stenoses was
demonstrated in our study.
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To the Editor: We read with great interest the recent paper by
Suissa et al.1 The authors found that the use of angiotensin-
converting enzyme inhibitors (ACEI) by patients with
diabetes was not associated with long-term decreased risk
of renal failure. Their findings suggested instead a higher risk
of renal failure in those who took ACEI, even after having
adjusted for other risk factors.
In our previous publication,2 where we reported that
ACEI/angiotensin II receptor antagonist (ATRA) therapy
decreases proteinuria by improving glomerular permselec-
tivity in IgA nephritis, we found ATRA to be superior. Our
data showed that majority of the non-responders were on
ACEI compared to the responders who were on ATRA
(w2¼ 6.3, Po0.02; Table 1a), suggesting that ATRA is more
effective in decreasing proteinuria. In this respect, we are not
surprised by the data of Suissa et al.,1 who showed that ACEI
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was not protective of end-stage renal failure. We studied
another 75 patients who entered a randomized controlled
trial (37 were on treatment and 38 controls) from 1999 to
2000 and were followed up for 5 years. Leaving out patients
on combined therapy, we again found that patients on ACEI
alone had a significantly higher incidence of progression to
end-stage renal failure when compared to those on ATRA
alone (Table 1b).
It is our belief that ATRA is superior to ACEI. Apart from
its ability to reduce or block the effects of ACE, ATRA by
itself has other renoprotective abilities like reducing trans-
forming growth factor-b production in the glomerulus,
which causes mesangial cell proliferation and contraction. In
diabetic nephropathy and IgA nephropathy, mesangial cell
injury is one of the main events in glomerular injury leading
to glomerular sclerosis.3 It would be interesting for Suissa
and co-workers to examine their data regarding the role of
ATRA in preventing end-stage renal failure.
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To the Editor: Suissa et al.1 reported on the risk of renal
failure in diabetics treated with angiotensin-converting
enzyme (ACE) inhibitors. They used a nested case–control
design and thus excluded over 1800 patients from the final
analysis. It is not clear why the entire cohort could not have
been analyzed to address the issue of mortality. ACE
inhibitors are intentionally prescribed to reduce mortality2
and to prolong time to dialysis.3 It would be informative for
the readers if the authors presented data for these two
outcomes both separately and combined (e.g. death, dialysis,
or transplant) for those prescribed ACE inhibitors and those
not, using the entire cohort of 6102 patients. Only with this
information can the readers determine if their conclusions
are valid. As the authors themselves state ‘ACE inhibitors
prolong life, thus increasing the opportunity for end-stage
renal disease incidence’.1 In addition, a stepped-care
approach to hypertension was often used in the era of this
study.4 As such, ACE inhibitors may have been prescribed to
patients with difficult to control blood pressure. It would be
useful to know if the database had any blood pressure values
and if there were any differences between the groups, as the
severity of hypertension is arguably the single most
important factor for progression of diabetic nephropathy.
In view of the above comments, the conclusion that ACE
inhibitors may increase the risk of renal failure in diabetes
may not be justified.
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To the Editor: Recently, Suissa et al.1 reported that use of
ACE inhibitors (ACEi) by hypertensive diabetic patients is
not associated with a long-term decreased risk of end-stage
renal disease. They suggest that ACEi while providing an early
benefit to the kidney could in fact damage the kidney in the
longer term by mechanisms still unknown.
Experimental data from our group support the possibility
of such adverse effects of renin–angiotensin system blockade
Table 1 | (a) Anti-proteinuric response to ACEI/ATRA therapy
and (b) comparing ACEI with ATRA therapy among
37 patients
ACEI ATRA
(a)
Responders (n=9) 2 7
Non-responders (n=7) 6 1
Pearson’s w2 6.3 (Po0.02)
(b)
Normal renal function 1 16
ESRF 5 7
Pearson’s w2 5.5 (Po0.02)
ACEI, angiotensin-converting enzyme inhibitor; ATRA, angiotensin II receptor
antagonist; ESRF, end-stage renal failure.
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